Innoviva's (INVA) Stock Is Thriving With Strategic Investments Pay-Off
Innoviva (NASDAQ:INVA) Investors Are up 6.3% in the Past Week, but Earnings Have Declined Over the Last Five Years
Innoviva (NASDAQ:INVA) Shareholders Have Earned a 36% Return Over the Last Year
Express News | Cantor Fitzgerald Reiterates Overweight on Innoviva
Cantor Starts Innoviva at Overweight, Cites Diversified Business Model
Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs
Innoviva Analyst Ratings
Cantor Fitzgerald Initiates Innoviva(INVA.US) With Buy Rating
Express News | Innoviva Inc : Cantor Fitzgerald Initiates Coverage With Overweight Rating
21% Of This Innoviva Insider's Holdings Were Sold
Calculating The Fair Value Of Innoviva, Inc. (NASDAQ:INVA)
Boston Pharmaceuticals Appoints Dr. Margaret Koziel as New Chief Medical Officer
Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Zai Lab, Innoviva Subsidiary Receive China Approval for Hospital Infection Treatment
Zai Lab, Innoviva: China Oks XACDURO For Hospital-Acquired, Ventilator-Associated Pneumonia In 18+
Zai Lab And Innoviva Specialty Therapeutics Announce NMPA Approval For XACDURO(R) (Sulbactam-Durlobactam Or SUL-DUR) For Hospital-Acquired And Ventilator-Associated Pneumonia Caused By Acinetobacter Baumannii-Calcoaceticus Complex In China >ZLAB
Innoviva Updates Investor Presentation on Website
Innoviva Inc (INVA) Reports First Quarter 2024 Earnings: A Detailed Analysis
Innoviva Q1 EPS $0.46 Beats $0.17 Estimate, Sales $77.50M Beat $68.00M Estimate
Innoviva | 10-Q: Quarterly report